title: Metabolic effects of combined cyproterone acetate and percutaneous 17 beta oestradiol after six and twelve months therapy in 61 patients.
abstract: The metabolic effects of combined cyproterone acetate (50 mg) and percutaneous 17 beta oestradiol were studied during one year in 61 patients admitted for hyperandrogenia. Before treatment and at 6 and 12 months the following tests were performed: oral glucose tolerance test (OGTT) with insulinemia dosage, determination of total cholesterol, LDL, VLDL and HDL fractions, triglycerids, A1 and B apoproteins, liver function tests: bilirubinemia, alkaline phosphatases, transaminases and gamma glutamyl transferases. The patients' mean age was 27.0 +/- 6.8 years, the body mass index was 22.4 +/- 3.5 kg/m2. After one year of treatment the body mass index was not modified. Blood glucose slightly increased during OGTT; at 6 months this was significant at +30 minutes, at 12 months at +30, +60 and +90 minutes (P less than 0.05). There was no variation in insulinemia during OGTT. Total cholesterol decreased significantly at 6 and 12 months (P less than 0.001), this was associated with a decrease in HDL cholesterol, but without modification of the LDL + VLDL/HDL ratio. Decrease in HDL cholesterol was associated with a significant decrease in A1 apoproteins. No change in triglycerids and in liver function tests was observed at either date. In conclusion the metabolic effects of this association are described. These effects are minimal compared to those observed with cyproterone acetate and ethinyl oestradiol association in the literature. However, attention should be drawn to the possibility of glucose intolerance and decrease in HDL cholesterol and A1 apoproteins.
authors.affiliation: Endocrinology and Diabetology Department, Hôpital Saint Louis, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Vexiau
authors.forename: B
authors.initials: B
authors.lastname: Gueux
authors.forename: D
authors.initials: D
authors.lastname: Vexiau-Robert
authors.forename: J
authors.initials: J
authors.lastname: Fiet
authors.forename: C
authors.initials: C
authors.lastname: Laureaux
authors.forename: F
authors.initials: F
authors.lastname: Tabuteau
authors.forename: J L
authors.initials: JL
authors.lastname: Brerault
authors.forename: J
authors.initials: J
authors.lastname: Mathieson
authors.forename: G
authors.initials: G
authors.lastname: Cathelineau
mesh_terms: D000328:Adult; D000728:Androgens / Q000378:metabolism*; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D003534:Cyproterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017373:Cyproterone Acetate; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism
chemical_list: D000728:Androgens; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D001786:Blood Glucose; D008076:Cholesterol, HDL; D007328:Insulin; D008055:Lipids; D017373:Cyproterone Acetate; D004958:Estradiol; D003534:Cyproterone